Drugs / rHSC-DIPGVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04943848 | Jan 2022 → Sep 2026 overdue | diffuse midline glioma, H3 K27M-mutant | Ann & Robert H Lurie Children's Hospital of Chicago | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHSC-DIPGVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04943848 ↗ |
| Modality | Vaccine | “Off-the-shelf, neoantigen heat shock protein vaccine” NCT04943848 ↗ |